29,143 Results

Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials.

Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking.

Cariprazine: A Review in Schizophrenia.

Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant...

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.

Objective: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.

Baxter International Inc.has announced the publication of "Fish Oil Containing Lipid Emulsions in Adult Parenteral Nutrition: A Review of the Evidence" in the Journal of Parenteral and Enteral Nutrition.

 Added 1 day ago

Baxter International Inc.has announced the publication of "Fish Oil Containing Lipid Emulsions in Adult Parenteral Nutrition: A Review of the...

The FDA has accepted for review a Biologics License Application (BLA) for a biosimilar candidate (TPI-G-CSF) referencing Neupogen (filgrastim).- Adello Biologics.

 Added 1 day ago

Adello Biologics announced that FDA has accepted for review the company’s Biologics License Application (BLA) for a biosimilar candidate (TPI-G-CSF)...

CHMP recommends Cyltezo (adalimumab biosimilar) to treat multiple chronic inflammatory diseases based on clinical equivalence to Humira (adalimumab), the reference product.- Boehringer.

 Added 1 day ago

Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

FDA approves supplemental indication for Somatuline Depot (lanreotide) in carcinoid syndrome.- Ipsen.

 Added 1 day ago

Ipsen announced that the FDA has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment...

Teva sells ParaGard, an intrauterine copper contraceptive device to Cooper Companies for $1.1 billion.

 Added 1 day ago

The Cooper Companies has agreed to buy ParaGard, an intrauterine copper contraceptive brand from Teva Pharmaceutical Industries for $1.1 billion...

Phase III LEAP 1 trial of BC 3781 (lefamulin) meets primary endpoint in community-acquired bacterial pneumonia.- Nabriva Therapeutics.

 Added 1 day ago

Nabriva Therapeutics announced positive topline results from the BC 3781 (lefamulin) evaluation against pneumonia (LEAP 1) trial, which evaluated the...

FDA approves Solosec (secnidazole) for treatment of bacterial vaginosis.- Symbiomix Therapeutics.

 Added 1 day ago

Symbiomix Therapeutics announced the FDA has approved Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in...

Load more